更新于：2024-11-21

Tetracycline Hydrochloride

盐酸四环素

更新于：2024-11-21

概要

概要

基本信息

药物类型

小分子化药

别名

(4S,4aS,5aS,12aS)-4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide、Abramycin、Anhydrotetracycline

+ [21]

靶点

30S subunit

作用机制

30S subunit抑制剂(30S核糖体亚基抑制剂)、蛋白质生物合成抑制剂

治疗领域

免疫系统疾病感染神经系统疾病+ [7]

在研适应症

感染急性支气管炎炭疽+ [25]

非在研适应症-

原研机构

Heritage Pharmaceuticals, Inc.

在研机构

Sun Pharma Japan Ltd.Heritage Pharmaceuticals, Inc.

天津金耀药业有限公司

非在研机构-

最高研发阶段批准上市

首次获批日期

美国 (1957-10-08)

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

结构

分子式C22H24N2O8

InChIKeyOFVLGDICTFRJMM-WESIUVDSSA-N

CAS号60-54-8

查看全部结构式(2)

关联

项与盐酸四环素相关的临床试验

CTRI/2024/08/072791 / Not yet recruiting临床4期IIT

Comparing the Effectiveness of Tetracycline Hydrochloride Fiber with Oxygen Releasing Gel as an adjunct to Scaling and Root Planing in Periodontitis patients - A Randomized Controlled Trial

开始日期2024-08-31

申办/合作机构-

NCT06509139 / Enrolling by invitation临床4期IIT

Optimal Treatment Duration of Bismuth Quadruple Therapy for Helicobacter Pylori Eradication in Female Patients and Comparison of the Efficacy with That of Male Patients

Helicobacter pylori eradication can reduce the risk of gastric cancer and decrease the recurrence of ulcers. However, in recent years, the increasing antibiotic resistance of Helicobacter pylori has reduced the efficacy of clarithromycin-based triple therapy to below 80%. The recent studies, including real-world data and a clinical trial, have consistently found that females have poorer eradication rate of Helicobacter pylori as compared with males. In previous clinical trial, investigators discovered that the efficacy of a 10-day bismuth quadruple therapy was not inferior to a 14-day bismuth quadruple therapy. However, it remains to be investigated whether the 10-day bismuth quadruple therapy is still non-inferior to the 14-day regimen in females.
This project continues the clinical trial to investigate whether the efficacy of the 10-day bismuth quadruple therapy in females is inferior to that in males and whether the 14-day bismuth quadruple therapy is superior to the 10-day regimen in females. The ultimate goal is to establish that male patients can use the 10-day bismuth quadruple therapy with fewer side effects and without compromising efficacy as compared with the 14-day regimen; while female patients are recommended to use the 14-day bismuth quadruple therapy as it would be more effective than the 10-day regimen.
Considering sex in research is becoming increasingly important, as females have more antibiotic-resistant Helicobacter pylori infection than males. The bismuth quadruple therapy can overcome most resistance issues. Researching and comparing the difference in the efficacy of bismuth quadruple therapy for Helicobacter pylori eradication between females and males are of significant clinical importance and align with current research trends.

开始日期2024-07-09

申办/合作机构

National Cheng Kung University Hospital

NCT06351891 / Not yet recruiting临床4期IIT

Efficacy and Safety of Bismuth Quadruple Therapy Containing Cefuroxime and Tetracycline as First-line Therapy for Eradicating Helicobacter Pylori in Patients Allergic to Penicillin: A Multicenter, Randomized Controlled Study

The researchers collected untreated H. pylori positive patients from outpatient clinics. Subjects were randomly assigned to receive either 14 days of bismuth quadruple therapy with cefuroxime and tetracycline or 14 days of bismuth quadruple therapy with cefuroxime and levofloxacin for Helicobacter pylori eradication. After 6 weeks of treatment, subjects underwent another 13C urea breath test. Eradication rates, adverse reaction rates and patient compliance were calculated.

开始日期2024-04-01

申办/合作机构

山东大学齐鲁医院

100 项与盐酸四环素相关的临床结果

登录后查看更多信息

100 项与盐酸四环素相关的转化医学

登录后查看更多信息

100 项与盐酸四环素相关的专利（医药）

登录后查看更多信息

1,840

项与盐酸四环素相关的文献（医药）

2025-02-01·Food Chemistry

Solid phase extraction-surface enhanced Raman spectroscopy (SPE-SERS) test of antibiotic residues in Milk based on au@ MIL-101 NPs

Article

作者: Zhan, YiFang ; Chen, Qiao ; He, Ting ; Jin, Fengmei ; Gao, Mengyue ; Li, ZhiHao ; Wang, LiHua ; Yao, Qi ; Hu, Jiming

A SPE-SERS method was developed for the detection of several antibiotic residues in dairy products. Gold nanoparticles (Au NPs) encapsulated with an ultrathin Cr-MIL-101 shell (Au@Cr-MIL-101 NPs) have been synthesized, and the thickness of Cr-MIL-101 shell can be precisely controlled to 3 nm. As a superior solid phase extraction (SPE) adsorbent, Cr-MIL-101 acts as a shell layer to effectively enrich antibiotics within the localized surface plasmon resonance (LSPR) field of Au NPs, which enhances the SERS signal and eliminates background interference. The method can achieve highly sensitive and high-throughput detection for tetracycline hydrochloride, sulfapyridine and benzylpenicillin sodium in dairy products, and the detection limits (LOD) are as low as 2.237, 2.644 and 4.662 ppb respectively. The recoveries of antibiotic residues in spiked dairy products ranged from 72.31 % to 146.7 % with matrix effects (ME) of -15.13 % to 28.68 %. Thus, this method holds significant promise for rapid detection of antibiotics in milk.

2025-02-01·Journal of Environmental Sciences

A comparison increasing the photodegradation power of a Ag/g–C3N4 /CoNi–LDH nanocomposite: Photocatalytic activity toward water treatment

Article

作者: Richeson, Darrin ; Aliyan, Hamid ; Li, Yuning ; Fazaeli, Razieh

For environmental applications, it is crucial to rationally design and synthesize photocatalysts with positive exciton splitting and interfacial charge transfer. Here, a novel Ag-bridged dual Z-scheme Ag/g-C₃N₄/CoNi-LDH plasmonic heterojunction was successfully synthesized using a simple method, with the goal of overcoming the common drawbacks of traditional photocatalysts such as weak photoresponsivity, rapid combination of photo-generated carriers, and unstable structure. These materials were characterized by XRD, FT-IR, SEM, TEM UV-Vis/DRS, and XPS to verify the structure and stability of the heterostructure. The pristine LDH, g-C₃N_4, and Ag/g-C₃N₄/CoNi-LDH composite were investigated as photocatalysts for water remediation, an environmentally motivated process. Specifically, the photocatalytic degradation of tetracycline was studied as a model reaction. The performance of the supports and composite catalyst were determined by evaluating both the degradation and adsorption phenomenon. The influence of several experimental parameters such as catalyst loading, pH, and tetracycline concentration were evaluated. The current study provides important data for water treatment and similar environmental protection applications.

2025-01-01·Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy

Dual excitation channel ratiometric fluorescent probes for visual and fluorescent detection of anthrax spore biomarker and tetracycline hydrochloride

Article

作者: Gu, Qingyang ; Sun, Jia ; Wei, Jiaxin ; Er, Xinyu ; Jin, Haibo

Long-term and excessive use of tetracycline hydrochloride (TC) can lead to its accumulation in the environment, which can cause water contamination, bacterial resistance, and food safety problems. 2,6-Pyridine dicarboxylic acid (DPA) is a major biomarker of Bacillus anthracis spores, and its rapid and sensitive detection is of great significance for disease prevention and counter-terrorism. A bifunctional ratiometric fluorescent nanoprobe has been fabricated to detect DPA and TC. 3,5-dicarboxyphenylboronic acid (BOP) was intercalated into layered europium hydroxide (LEuH) by the ion-exchange method and exfoliated into nanosheets as a fluorescent nanoprobe (PNP). DPA and TC could significantly enhance the red fluorescence of Eu³⁺ through the antenna effect under different excitation wavelengths, while the fluorescence of BOP can be used as a reference based on the constant emission intensity, realizing ratiometric detection. A low limit of detection (LOD) for the target (DPA: 9.7 nM, TC: 21.9 nM) can be achieved. In addition, visual detection of DPA and TC was realized using color recognition software based on the obvious color changes. This is the first ratiometric fluorescent nanoprobe based on layered rare-earth hydroxide (LRH) for the detection of DPA and TC simultaneously, which opens new ideas in the design of multifunctional probes.

项与盐酸四环素相关的新闻（医药）

2024-07-31

·奇点网

山东临朐666，老乡又立功了

*仅供医学专业人士阅读参考从某种程度上说，胃癌算是最典型的“病从口入”型癌症，因为幽门螺杆菌（Hp）这个头号致癌因素就主要经口传播，而在胃癌高发的我国，全人群的Hp感染率估测有40-50%，奇点糕每次看到数据都觉得心惊[1]。所以想要取得胃癌防治的突破，就得用三联乃至四联疗法对Hp感染重拳出击，根除感染来降低胃癌发病风险，其成效也已经被许多研究证实。而今天，北京大学肿瘤医院游伟程、李文庆、潘凯枫团队与德国慕尼黑工业大学团队合作，于山东省临朐县开展的一项集群随机对照试验结果发表在了《自然·医学》上[2]，这项纳入超过18万参与者、中位随访时间11.8年的大规模干预试验证实，筛查并针对Hp感染进行治疗（四联疗法），可使参与者随访期内的胃癌发病风险显著下降14%（HR=0.86）。而经四联疗法成功根除Hp感染的参与者，获益相对就更明显（HR=0.81），且针对Hp感染的治疗整体也相当安全，因此这项大规模试验结果进一步显示，在全人群中展开针对Hp感染的筛查和治疗，是降低胃癌发病率的有效公共卫生策略。论文首页截图如果在座各位对我国胃癌防治和研究史有所了解，看到临朐这个地名应该会有相当的熟悉感，早在上世纪80年代，由于胃癌发病率几乎高居全国之首，临朐就被确定为胃癌防治的“研究现场”，北京大学肿瘤医院团队已经在当地开展了40年的工作，并以一项随机对照试验的长期随访结果（随访22年），证实了治疗Hp感染对降低胃癌发病风险的有效性[3]。不过正如奇点糕此前所说，我国的Hp感染人数真的“数以亿计”，纳入2000多名参与者的随机对照试验，相比起来规模还是偏小了一些，2014年世卫组织国际癌症研究机构（IARC）专家组就指出，各种小规模临床研究的证据等级还稍显不足，于是就有了本次中德学者合作于2011年启动，面向更年轻人群（参与者年龄为25-54岁）的大规模干预试验（MITS）。此前在2015年，研究者们已报告了试验参与者的基线情况，以及使用四联疗法根除Hp感染的疗效：全部参与者的Hp感染率为57.6%，而在接受四联疗法的9.4万余名参与者中，Hp感染的根除率为72.9%[4]；而本次见刊的则是试验中位随访11.8年时的数据，试验的随访率是极高的，仅有0.02%（42名）参与者失访，参与者中共计新发1035例胃癌。分析结果表明，在意向治疗人群（ITT）中，针对Hp感染的四联疗法治疗10天（20毫克奥美拉唑、750毫克四环素、400毫克甲硝唑和300毫克柠檬酸铋，n=52026），可使感染Hp参与者的胃癌发病风险，较接受症状缓解治疗（奥美拉唑+柠檬酸铋，n=50304）的Hp感染者降低14%，成功根除Hp感染的参与者则有更多获益，但治疗失败者风险并未下降。抗Hp感染治疗对比症状缓解治疗及Hp阴性人群的发病风险情况事后分析显示，四联疗法主要降低了参与者非贲门癌的发病风险（HR=0.66，贲门癌HR则为1.11），且仅45岁以下参与者的获益有统计学显著性；不过，四联疗法并未体现降低参与者胃癌死亡风险的显著效果（HR=0.89, 95% CI: 0.72-1.11），即使成功根除Hp感染也是如此。此外，四联疗法对患者全因死亡风险和其它癌症发病风险也无明显影响。分类更为详细的事后分析数据而在10天的四联疗法治疗期间，共有1345名参与者报告了中度不良反应，但在治疗或后续随访期间，未观察到参与者发生严重或无法忍受的不良事件，这对大规模推广抗Hp感染当然是好事儿。研究者们在论文中就推算，将这种策略在全国推开，每年保守估计就能减少8.5万例新发胃癌，真不是个小数目啦，奇点糕着实希望看到这个画面成真参考文献：[1]Ren S, Cai P, Liu Y, et al. Prevalence of Helicobacter pylori infection in China: A systematic review and meta‐analysis[J]. Journal of Gastroenterology and Hepatology, 2022, 37(3): 464-470.[2]Pan K-F, Li W-Q, Zhang L, et al. Gastric cancer prevention by community eradication of Helicobacter pylori: a cluster-randomized controlled trial[J]. Nature Medicine, 2024.[3]Li W Q, Zhang J Y, Ma J L, et al. Effects of Helicobacter pylori treatment and vitamin and garlic supplementation on gastric cancer incidence and mortality: follow-up of a randomized intervention trial[J]. BMJ, 2019, 366.[4]Pan K, Zhang L, Gerhard M, et al. A large randomised controlled intervention trial to prevent gastric cancer by eradication of Helicobacter pylori in Linqu County, China: baseline results and factors affecting the eradication[J]. Gut, 2016, 65(1): 9-18.本文作者丨谭硕

2024-04-22

·奇点网

抗生素还能这样用啊

*仅供医学专业人士阅读参考四环素是从土壤放线菌中发现的天然产物，以其广谱抗菌活性而闻名，于1948年首次在科学文献中报道，在20世纪40年代末至1950年代初开始商业化并在临床上取得成功。目前常见的四环素类抗生素包括多西环素、米诺环素、四环素、地美环素（去甲金霉素）等。除了抗菌，四环素类抗生素还具有抗炎和免疫调节等方面的作用，使其成为某些皮肤病和风湿性疾病的治疗选择，但对抗肿瘤T细胞免疫的影响仍有待阐明。近日，日本大坂大学的Kota Iwahori团队发表在《癌症免疫治疗杂志》上的最新研究成果，揭示四环素类抗生素可以通过增强T细胞受体信号传导、促进Zap70磷酸化，来增强T细胞的细胞毒性。体外实验提示四环素类抗生素与PD-1抑制剂具有协同作用，使用四环素类抗生素治疗小鼠时可增加肿瘤抗原特异性T细胞数量。论文首页截图为了能够高效地给癌症免疫疗法找到合适辅助，科学家们不断尝试老药再利用。例如，2型糖尿病治疗药物二甲双胍，有报告显示，它能通过刺激肿瘤浸润CD8阳性T细胞的线粒体活性来发挥免疫介导的抗肿瘤效；高脂血症治疗药物苯扎贝特，可以通过激活线粒体和细胞代谢来增加和维持小鼠肿瘤的细胞毒性T细胞的数量，从而增强PD-1抑制剂疗效。这些研究展示了现有药物在癌症免疫治疗领域的潜力，也为癌症治疗开辟了新的方向。在这项研究中，研究者们采用双特异性T细胞接合器（BiTE）技术，评估不同培养条件下T细胞对肿瘤细胞的细胞毒性。他们将健康捐赠者的外周血单个核细胞（PBMCs）与人胶质瘤细胞（U251）共培养，发现与不添加四环素类抗生素相比，米诺环素、地美环素在0.1µM和1µM的浓度下能够显著增强T细胞，尤其是CD8阳性T细胞的细胞毒性，增加其GzmB 、IFN-γ等杀伤因子的表达；而在没有T细胞的情况下，四环素类抗生素不显示直接的抗肿瘤细胞毒性。四环素类抗生素提高T细胞的细胞毒性此外，体外结果还显示，米诺环素与PD-1抑制剂（纳武利尤单抗）的联合使用具有协同效应，能够增强健康捐赠者的PBMCs和非小细胞肺癌（NSCLC）患者手术切除的肿瘤浸润T细胞的抗肿瘤活性。从临床相关性来看，在接受EGFR-TKIs一线治疗后PD-1抑制剂治疗的EGFR突变型NSCLC患者中，与未接受米诺环素治疗相比，接受米诺环素治疗的患者中位总生存期（OS）更长（37.8个月 vs 18.6个月，p=0.041）。四环素类抗生素使用与PD-1抑制剂治疗具有协同作用以上结果表明，米诺环素具有增强免疫治疗敏感性的潜力。进一步研究揭示了米诺环素的抗肿瘤免疫机制。研究表明，米诺环素能够增强T细胞上的T细胞受体（TCR）信号传导，使其通路中关键信号蛋白Zap70的磷酸化和Nur77的表达增加，从而增强T细胞的活性和细胞毒性，提升T细胞对肿瘤细胞的攻击能力。另一方面，研究者们从188种能够与四环素类抗生素结合的蛋白质中，也找出了端倪。已有研究证明，肿瘤细胞分泌的半乳糖凝集素-1是抗肿瘤T细胞和自然杀伤细胞（NK）的有效抑制剂，帮助肿瘤细胞逃避免疫系统的攻击。这里表明，米诺环素通过与肿瘤细胞表达的半乳糖凝集素-1结合，解除了抑制作用，间接增强了T细胞、NK细胞的细胞毒性。体外实验中，没有观察到PD-1抑制剂处理对TCR信号传导的这种影响，也就是说四环素类抗生素与PD-1抑制剂的作用机制并不相同。研究者们利用乳腺癌、结直肠癌小鼠模型，评估了地美环素的药代动力学和抗肿瘤效果。结果显示，每天两次口服3、10、30mg/kg剂量的地美环素，小鼠肿瘤体积明显小于未治疗对照组，不同剂量间疗效差异不大；同时，观察到地美环素治疗增加了肿瘤抗原特异性T细胞，且IFN-γ等杀伤因子水平提高，表明T细胞抗肿瘤活性得到增强。四环素类抗生素给药减少肿瘤体积这些结果揭示，四环素类抗生素通过Zap70信号传导增强T细胞抗肿瘤免疫。不过四环素类抗生素要想成为免疫治疗的新帮手，未来还需要进一步阐明其中潜在的作用机制，衡量四环素类抗生素带来的自身免疫副作用，以有助于新型癌症免疫疗法的开发。参考文献：[1]https://jitc.bmj.com/content/12/4/e008334本文作者丨张艾迪

免疫疗法

2024-03-29

·米内网

【火热】17亿明星滴眼液，痔疮用药“一哥”入局

精彩内容3月29日，江西马应龙美康药业提交了玻璃酸钠滴眼液4类仿制上市申请。该产品是一款明星滴眼液，2022年在中国三大终端六大市场（统计范围见文末）的合计销售额超过17亿元。马应龙是国内中成药痔疮用药龙头企业，近几年公司持续加码眼科药物，目前有4款化药滴眼液报产在审。图1：马应龙最新申报的产品情况来源：CDE官网玻璃酸钠滴眼液用于眼睛疲劳、眼干燥症、眼干燥综合症等内因性疾患，手术后药物性、外伤、光线对眼造成的刺激及戴隐形眼镜等引起的外因性疾病。图2：玻璃酸钠滴眼液在零售药店终端的销售情况（单位：万元）来源：米内网格局数据库米内网数据显示，2022年在中国三大终端六大市场，玻璃酸钠滴眼液的合计销售额超过17亿元。近几年该产品在零售药店终端（城市实体药店+网上药店）的销售额保持高速增长态势，2022年合计达到了9亿元以上，零售药店终端已成为玻璃酸钠滴眼液的销售主阵地。图3：马应龙已上市的眼科药物来源：米内网中国上市药品（MID）数据库早前，马应龙已拥有马应龙八宝眼膏、马应龙八宝眼粉两款眼科中成药，以及复方右旋糖酐70滴眼液、萘敏维滴眼液、氯霉素眼膏、四环素眼膏、四环素可的松眼膏、红霉素眼膏6款眼科化药。2023年公司陆续报产了盐酸莫西沙星滴眼液、地夸磷索钠滴眼液、盐酸丙美卡因滴眼液，本次申报的玻璃酸钠滴眼液为公司2024年首款报产的眼科化药，这4款滴眼液加速冲刺，未来将成为公司在眼科药物领域的重磅成员。资料来源：CDE官网、米内网数据库等注：米内网《中国三大终端六大市场药品竞争格局》，统计范围是：城市公立医院和县级公立医院、城市社区中心和乡镇卫生院、城市实体药店和网上药店，不含民营医院、私人诊所、村卫生室，不含县乡村药店；上述销售额以产品在终端的平均零售价计算。数据统计截至3月29日，如有疏漏，欢迎指正！本文为原创稿件，转载请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092【分享、点赞、在看】点一点不失联哦

专利侵权

100 项与盐酸四环素相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D02122	盐酸四环素	J01AA07 S02AA08 S03AA02 S01AA09 D06AA04 A01AB13	DB00759

研发状态

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
急性支气管炎	日本	Sun Pharma Japan Ltd.	1964-12-01
脑脓肿	日本	Sun Pharma Japan Ltd.	1964-12-01
膀胱炎	日本	Sun Pharma Japan Ltd.	1964-12-01
淋病	日本	Sun Pharma Japan Ltd.	1964-12-01
肉芽肿	日本	Sun Pharma Japan Ltd.	1964-12-01
子宫内感染	日本	Sun Pharma Japan Ltd.	1964-12-01
肺脓肿	日本	Sun Pharma Japan Ltd.	1964-12-01
乳腺炎	日本	Sun Pharma Japan Ltd.	1964-12-01
骨髓炎	日本	Sun Pharma Japan Ltd.	1964-12-01
牙周炎	日本	Sun Pharma Japan Ltd.	1964-12-01
肺炎	日本	Sun Pharma Japan Ltd.	1964-12-01
肾盂肾炎	日本	Sun Pharma Japan Ltd.	1964-12-01
鼻窦炎	日本	Sun Pharma Japan Ltd.	1964-12-01
皮肤和皮肤结构感染	日本	Sun Pharma Japan Ltd.	1964-12-01
扁桃体炎	日本	Sun Pharma Japan Ltd.	1964-12-01
土拉菌病	日本	Sun Pharma Japan Ltd.	1964-12-01
地方性斑疹伤寒	日本	Sun Pharma Japan Ltd.	1964-12-01
百日咳	日本	Sun Pharma Japan Ltd.	1964-12-01
继发感染	日本	Sun Pharma Japan Ltd.	1963-06-22

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04716426 (CTgov)	N/A	新型冠状病毒感染	100	Tetracycline hydrochloride 3% (Tetracycline Hydrochloride 3%)	顧鬱艱艱齋憲願鑰鏇鹽(糧餘製衊憲夢鑰製襯簾) = 範襯簾餘廠網繭膚餘顧範壓觸簾淵簾襯觸顧願 (鏇齋鑰簾膚壓醖觸鹹窪, 鑰齋壓簾遞艱簾憲艱遞 ~ 鹹範廠齋鹹醖顧廠觸築) 更多	-	2021-04-08
				Placebo (Placebo)	顧鬱艱艱齋憲願鑰鏇鹽(糧餘製衊憲夢鑰製襯簾) = 餘簾繭選膚選夢繭鹹鹽範壓觸簾淵簾襯觸顧願 (鏇齋鑰簾膚壓醖觸鹹窪, 廠醖鏇願鑰衊憲鹽鹽築 ~ 範夢窪網糧顧糧醖衊願) 更多
NCT02547038 (CTgov)	N/A	幽门螺杆菌感染	352	pantoprazole+tetracycline+metronidazole+bismuth subcitrate (Pantoprazole+Bismuth+Tetra+Metro)	積網構獵衊鏇鑰製顧鹽(繭糧糧製選襯範鹽顧艱) = 網壓遞鹹鹹鏇齋繭鑰蓋繭觸獵餘遞夢鑰醖鹹鏇 (壓鬱窪襯簾醖廠襯蓋憲, 遞鹽顧膚選積醖製選齋 ~ 醖網壓鹽顧網築膚網範) 更多	-	2019-06-10
				pantoprazole+amoxicillin+metronidazole+clarithromycin ((Panto+Amox+Clar+Metr)+(Panto+Amox))	積網構獵衊鏇鑰製顧鹽(繭糧糧製選襯範鹽顧艱) = 夢顧繭簾構憲範築鏇觸繭觸獵餘遞夢鑰醖鹹鏇 (壓鬱窪襯簾醖廠襯蓋憲, 糧製壓繭築襯願鹽築築 ~ 壓齋網艱構淵鑰構範範) 更多
NCT02547012 (CTgov)	N/A	幽门螺杆菌感染	51	levofloxacin+amoxicillin +tetracycline+esomeprazole (Esomeprazole+Amox+Levo+Tetra)	鑰憲選蓋衊積夢齋窪衊(糧遞鏇壓壓夢遞範憲願) = 繭糧齋醖糧鬱範膚鑰選範廠鬱顧廠膚鬱窪範構 (觸餘窪膚鑰積窪願窪簾, 鹹壓繭願觸顧蓋憲夢廠 ~ 選餘艱壓襯繭襯鏇齋獵) 更多	-	2019-03-14
				amox+esomeprazole (Esomeprazole+Amox+Levo)	鑰憲選蓋衊積夢齋窪衊(糧遞鏇壓壓夢遞範憲願) = 衊衊鑰蓋襯鏇製齋選網範廠鬱顧廠膚鬱窪範構 (觸餘窪膚鑰積窪願窪簾, 鑰蓋廠鬱餘構鬱膚醖夢 ~ 醖餘壓廠鹽蓋選獵膚淵) 更多
NCT01753856 (CTgov)	临床4期	骨质疏松症	69	Demeclocycline+Teriparatide+Tetracycline+Vitamin D (Teriparatide)	獵範淵窪夢夢醖鹽憲艱(鹹製廠構構鏇遞醖窪餘) = 鏇繭襯鏇構餘範鑰遞構醖憲製蓋願糧鏇齋簾夢 (鏇願壓製鏇壓鑰鏇憲顧, 衊淵艱膚鹽築窪鹹製蓋 ~ 鹹範醖衊衊範遞繭夢觸) 更多	-	2015-10-08
				Demeclocycline+Tetracycline+Vitamin D+Denosumab (Denosumab)	獵範淵窪夢夢醖鹽憲艱(鹹製廠構構鏇遞醖窪餘) = 製鏇廠顧衊遞獵鬱築壓醖憲製蓋願糧鏇齋簾夢 (鏇願壓製鏇壓鑰鏇憲顧, 獵築願願艱觸鬱網鏇願 ~ 夢淵繭憲衊窪願糧製觸) 更多